Immunyx selected as a Resident Quick Fire Challenge Partnering for Preparedness Recipient

June 2024

We are thrilled to be announced as one of the awardees for the #BLUEKNIGHT #QuickFireChallenge. Inspired to continue innovating for a better and safer future. Thank you to our project partners at Akagera Medicines, Inc and the great team at VLX Ventures who continues to support our vision.

Targeted nanoparticles modify neutrophil function in vivo

October 2022

Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil...

Immunyx selected as a Quick Fire Challenge Project Nextgen Recipient

September 2023

The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation are thrilled to announce...

Immunyx selected as a BlueKnight Company

January 2023

Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected...

Hero image immunyX

Contact Us

Immunyx strives to improve disease treatment. If you’re interested in our mission we would love to hear from you.